Compare Marvell Technology Inc (MRVL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs BIO-TECHNE Corp — how do they compare? Marvell Technology Inc trades at $233.47 (market cap $200.91B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Marvell Technology Inc is far larger — about 17.7× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.
| MRVL | TECH | |
|---|---|---|
Market Cap | $200.91B | $11.34B |
Sector | Technology | Health |
52-Week High | $316.43 | $72.48 |
52-Week Low | $66.59 | $43.31 |
Enterprise Value | $202.26B | $11.36B |
Dividend Yield | 0.11% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $225.41, up 0.83% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth projections, with management forecasting $12 billion for fiscal 2026 and $18 billion for 2027. Despite negative net income in recent periods, the company has consistently beaten EPS expectations and maintains strong profitability margins. Technical indicators show bullish moving averages with support at $221 and resistance at $231.
Marvell presents significant growth potential driven by AI chip demand, with an 82% analyst buy rating and $303 consensus price target representing 34% upside. Key risks include intense competition from Broadcom, customer concentration, and high valuation multiples. The October Investor Day could serve as a catalyst for further price appreciation if growth projections are reaffirmed.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
